Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07238465 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome

Study acronym: DIVE
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Dec 2028 → Dec 2029
Primary endpoints removed 43 → 21 primary endpoints
See other at-risk trials from University of Colorado, Denver

Record History

  1. Notable Primary completion pushed from Dec 2028 to Dec 2029 Primary endpoint(s) modified · Completion pushed from Dec 2029 to Dec 2030 · Interventions modified · 3 more Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Completion pushed from Dec 2029 to Dec 2030
    • Interventions modified
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: 9 to 3
    • Study description shortened, about 6 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2025 to Apr 6, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2025 to Apr 6, 2026
    • Site details revised
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Down syndrome (DS), the most common genetic cause of intellectual disability, is associated with widespread organ dysfunction, including abnormalities in the autonomic nervous system (ANS). The ANS regulates critical functions such as heart rate (HR) and blood pressure (BP), both essential for maintaining homeostasis and supporting physical activity. Individuals with DS often exhibit blunted HR responses to exercise-typically \~30 beats per minute below expected levels-suggesting reduced sympathetic nervous system (SNS) activity. The SNS governs rapid changes in HR and BP during stress by releasing catecholamines: epinephrine (from the adrenal medulla) and norepinephrine (from sympathetic nerve endings). Despite its importance, SNS function has not been comprehensively assessed among individuals with DS. This study addresses a critical knowledge gap by evaluating SNS responses to physiological stressors in individuals with DS. The investigators will measure beat-to-beat HR and BP, along with plasma catecholamine levels, in response to sympathetic activation, comparing individuals with DS to age- and sex-matched controls. Understanding the mechanisms of SNS dysfunction in DS is vital, as it likely underlies reduced exercise capacity and contributes to broader clinical challenges. These insights may guide targeted interventions to improve cardiovascular function, physical capacity, and overall quality of life in this understudied population.
Trial Details
NCT Number NCT07238465
Lead Sponsor University of Colorado, Denver
Collaborators: National Institute on Aging (NIA), Linda Crnic Institute for Down Syndrome, GLOBAL Down Syndrome Foundation, University of Colorado Colorado Clinical and Translational Sciences Institute
Conditions Down Syndrome, Autonomic Dysfunction
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov